Establishment Labs (NASDAQ:ESTA) Shares Gap Down - Time to Sell?

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) shares gapped down prior to trading on Friday . The stock had previously closed at $48.12, but opened at $42.49. Establishment Labs shares last traded at $47.63, with a volume of 131,713 shares changing hands.

Analysts Set New Price Targets

ESTA has been the topic of a number of recent analyst reports. Citigroup increased their price objective on Establishment Labs from $45.00 to $50.00 and gave the company a "neutral" rating in a report on Tuesday, October 1st. Stephens reiterated an "overweight" rating and issued a $68.00 price objective on shares of Establishment Labs in a report on Wednesday, August 7th. JPMorgan Chase & Co. decreased their target price on Establishment Labs from $61.00 to $50.00 and set an "overweight" rating for the company in a research report on Wednesday, August 7th. Finally, BTIG Research upped their target price on Establishment Labs from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Monday, October 14th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Establishment Labs currently has a consensus rating of "Moderate Buy" and an average price target of $58.83.

Establishment Labs Trading Down 3.9 %

The business has a 50-day moving average of $43.38 and a 200-day moving average of $45.91. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.91 and a current ratio of 4.44. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -14.87 and a beta of 1.20.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11). Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The company had revenue of $44.12 million for the quarter, compared to analyst estimates of $43.10 million. During the same period in the previous year, the business posted ($0.65) earnings per share. The firm's revenue was down 9.2% compared to the same quarter last year. As a group, research analysts forecast that Establishment Labs Holdings Inc. will post -2.27 EPS for the current year.

Institutional Trading of Establishment Labs

A number of hedge funds have recently added to or reduced their stakes in ESTA. Hood River Capital Management LLC acquired a new stake in shares of Establishment Labs in the 2nd quarter valued at approximately $43,000. Nkcfo LLC acquired a new stake in shares of Establishment Labs in the 2nd quarter valued at approximately $227,000. Concurrent Investment Advisors LLC acquired a new stake in shares of Establishment Labs in the 1st quarter valued at approximately $263,000. SG Americas Securities LLC acquired a new stake in shares of Establishment Labs in the 2nd quarter valued at approximately $303,000. Finally, Black Swift Group LLC acquired a new stake in shares of Establishment Labs in the 3rd quarter valued at approximately $312,000. 72.91% of the stock is owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.